MG
UPB

Michael Gelband’s Upstream Bio Inc UPB Stock Holding History

Michael Gelband’s Portfolio UPB Stock Details UPB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$284K Sell
41,045
-50,386
-55% -$422K ﹤0.01% 1370
2026
Q1 		$823K Buy
91,431
+16,029
+21% +$288K 0.01% 1046
2025
Q4 		$2.05M Buy
+75,402
New +$1.88M 0.02% 755

Other funds holding UPB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Michael Gelband's UPB Position: Q2 2026 in Review

Michael Gelband reduced its Upstream Bio Inc (UPB) stake by 55% in Q2 2026, selling an estimated $422K and leaving 41,045 shares worth $284K. The position accounts for ﹤0.01% of the portfolio, ranked #1370.

Michael Gelband first reported a position in UPB in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.05M in Q4 2025. 149 funds tracked by Wall St. Rank hold UPB as of Q2 2026.

  • Michael Gelband held 41,045 shares of Upstream Bio Inc worth $284K as of Q2 2026.
  • Michael Gelband sold 50,386 Upstream Bio Inc shares in Q2 2026, an estimated $422K.
  • Upstream Bio Inc made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1370 holding.
  • Michael Gelband first reported a position in Upstream Bio Inc in Q4 2025 and has held it in 3 quarters since.
  • Michael Gelband's Upstream Bio Inc position peaked at $2.05M in Q4 2025.
  • 149 funds tracked by Wall St. Rank held Upstream Bio Inc as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.